Anemia, Surgery, Arthroscopy
Conditions
Keywords
Anemia, erythropoetin, quality-of-life outcomes
Brief summary
The purpose of this study is to compare the effect of perioperative administration of PROCRIT to that of autologous blood donation on post-operative rehabilitation outcomes in patients undergoing unilateral knee surgery.
Detailed description
The primary objective of this study is to compare the effect of perioperative administration of PROCRIT to that of preoperative autologous donation on post-operative rehabilitation outcomes in subjects undergoing primary unilateral knee arthroplasty. Secondary objectives are : 1) To compare the effect of perioperative administration of PROCRIT to that of preoperative autologous donation on hemoglobin, change in hemoglobin, number of units transfused and transfusion rate during the study period; and 2) To compare the effect of perioperative administration of PROCRIT to that of preoperative autologous donation on inpatient rehabilitation length of stay. The study will test the hypothesis that perioperative administration of PROCRIT will improve post-operative rehabilitation outcomes, compared with preoperative autologous donation. 40,000U PROCRIT or Placebo SC in relation to surgery date: Days -21, -14, -7, 0 (day of surgery), 7, and 14.
Interventions
DRUGepoetin alfa
Sponsors
Ortho Biotech Products, L.P.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Scheduled for primary unilateral knee arthroplasty with an expected discharge into an inpatient rehabilitation facility * Hemoglobin \>11 to \<13 g/dL at screening and preoperative day -21 * Age 18 years or older * Female subjects must be post-menopausal for at least one year or surgically sterile (hysterectomy or tubal ligation). Women of childbearing age must have negative pregnancy test(s) (serum HCG RIA at screening and urine at preoperative day -21, if applicable * Preoperative lead time of at least 21 days
Exclusion criteria
* Medical conditions including: Known iron deficiency (defined as serum ferritin \<50 mg/l) * chronic renal failure, significant hematological disease, uncontrolled hypertension, new onset seizures/uncontrolled seizures * Expected to need another lower extremity major joint replacement within six months * Undergoing cancer chemotherapy * History of thrombotic vascular events including but not limited to stroke, transient ischemic attack, myocardial infarction and deep venous thrombosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the change in composite FIM scores (from entry into the inpatient rehabilitation facility to discharge from inpatient rehabilitation) divided by the LOS, denoted as DFIM/LOS, or rate of functional recovery. | — |
Secondary
| Measure | Time frame |
|---|---|
| LOS in the inpatient rehabilitation facility; Total FIM score; FIM Physical Sub-score LASA score; FACIT-An score. Safety evaluations include the incidence of adverse events throughout the study | — |
Outcome results
None listed